Norovirus Grown In Human Cells
News Nov 07, 2014
University of Florida researchers have grown a human norovirus in a cell culture dish, finally opening the door to developing medications for fighting the intestinal scourge that strikes tens of millions every year in schools, hotels and cruise ships worldwide.
“The biggest hurdle to doing norovirus research for its entire history -- it was discovered in 1972 -- has been that we can’t culture the human viruses in a cell culture dish,” said UF Health researcher Stephanie Karst, an associate professor in the department of molecular genetics and microbiology in the UF College of Medicine. “That complicates every aspect of research. We can’t study how it replicates, we can’t test therapeutics and we can’t generate live virus vaccines.”
A paper authored by Karst and her colleagues appears Friday, Nov. 7, in the journal Science. Noroviruses are pernicious intestinal viruses. They cause violent vomiting and diarrhea, and people ill with the virus remain contagious up to three days after they seem to recover.
Although a vaccine for these viruses is in clinical trials, there is still no medication to combat them. That’s in part because researchers have not been able to culture human noroviruses so they can test potential treatments — until now. According to the Centers for Disease Control and Prevention, in the United States, human noroviruses cause 19 million to 21 million cases of illness per year, and contribute to 56,000 to 71,000 hospitalizations and 570 to 800 deaths, mostly in young children and older adults. Noroviruses are resistant to many common disinfectants. Very little of the virus is needed to infect a host, so a surface may still contain enough virus to infect a person even after it is cleaned.
Previously, researchers speculated that noroviruses primarily target intestinal epithelial cells, which line the intestine and protect it from pathogens, Karst said. However, this new research demonstrates that the virus targets B cells, a type of white blood cell common in the intestine.
“That’s a big surprise,” Karst said. “You would think that any virus that’s going to target the intestine would instead target the intestinal epithelial cells because that’s the first cell the virus is going to encounter.”
Researchers also were surprised to find that bacteria present in the body’s gut flora, also known as commensal bacteria, helped the human norovirus infect B cells. Karst said scientists have long known that noroviruses need a particular kind of carbohydrate to infect cells.
“What we’ve shown is that noroviruses attach to that carbohydrate expressed on commensal bacteria, and that this interaction stimulates viral infection of the B cell,” Karst said. “This is a really exciting, emerging theme. A variety of intestinal viruses seem to exploit the bacteria that are present in our intestines all the time. These viral infections are enhanced by the presence of bacteria in the gut.”
UF research scientist Melissa Jones, a co-author on the paper, said the idea to study B cells came from Karst’s research on mouse noroviruses. UF scientists detected virus in Peyer’s patches, pockets of lymphoid nodules that line the intestine and survey the organ for pathogens.
“Ultimately, this system should open up new avenues for norovirus vaccine and antiviral drug development,” Karst said.
Chemicals in Lavender and Tea Tree Oil Could be Hormone DisruptorsNews
A new study lends further evidence to a suspected link between abnormal breast growth in young boys--called prepubertal gynecomastia--and regular exposure to lavender or tea tree oil, by finding that key chemicals in these common plant-derived oils act as endocrine-disrupting chemicals.READ MORE
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Comments | 0 ADD COMMENT
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018
World Congress on Plant Science and Molecular Biology
Sep 12 - Sep 13, 2018